Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | QTX-2101 + Tretinoin |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| QTX-2101 | SY 2101|SY2101|SY-2101|QTX 2101|QTX2101|ORH-2014|ORH2014|ORH 2014 | QTX-2101 is an oral formulation of arsenic trioxide, which potentially induces tumor cell apoptosis (PMID: 40020161, NCI Drug Dictionary) | ||
| Tretinoin | Vesanoid | Aberel|Aknoten|Avita|Renova|Retin-A|all-trans retinoic acid|Vitamin A Acid|ATRA | Vesanoid (tretinoin) is a form of retinoic acid, which binds to retinoic acid receptors and activates downstream signaling, potentially inducing cell differentiation and subsequently, apoptosis (PMID: 11704842). Vesanoid (tretinoin) is FDA approved for patients with acute promyelocytic leukemia harboring PML-RARA (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07504458 | Phase III | Arsenic trioxide + Tretinoin QTX-2101 + Tretinoin | Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia (QUATRO-APL) | Recruiting | USA | ROU | FRA | ESP | 0 |